Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA/China Import Safety MOU Will Be Signed Mid-December

This article was originally published in PharmAsia News

Executive Summary

HHS Secretary Mike Leavitt expects to finalize a memorandum of understanding for drug and medical device safety during his trip to China the week of Dec. 10, but the agreement will not include plans to establish a permanent FDA office in China

You may also be interested in...

China Beefs Up Regs For Drugs Containing Codeine, Online Distributors: SFDA Press Conference

SHANGHAI - China's State FDA will revoke the business licenses of companies that sell and distribute oral solutions containing codeine - a common painkiller and cough suppressant - without a doctor's prescription, SFDA said at its monthly press conference in Beijing, Dec. 8

PharmAsia News Business Bulletin

A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts